Biogen Takes Breather on Earnings and MS Drug Sales
Biogen Idec reported better-than-expected third-quarter results before the market opened Wednesday.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 280The Plan to Drive Amgen Shares Up Over 70%
Amgen Inc. (NASDAQ: AMGN) used to be the king of biotech by size. That was then, and now is the time for a break-up or other efforts. At least that is the case brought…
Why Everyone Likes Illumina Again
ThinkstockIllumina Inc. (NASDAQ: ILMN) reported its earnings before the market opened Monday as $0.77 in earnings per share and $481 in revenue which beat out consensus estimates. On the heels of this earnings report,…
Connecture Files for IPO: Health Care Insurance Platform
Connecture Inc. has filed with the Securities and Exchange Commission to have an initial public offering.
Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade
Goldman Sachs has initiated on MannKind with a Neutral rating and a $6 price target, a move that may seem to some as the equivalent to a downgrade.
Ebola Stock Fallout Severe on Monday
Some of the Ebola high-flying stocks saw their share prices crater on Monday as Ebola fears are subsiding for several reasons.
NewLink Scores Major Partners With Roche’s Genentech
NewLink Genetics announced that it has entered into an exclusive worldwide license agreement with Genentech for the development of NewLink's IDO pathway inhibitor.
Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential
A new report from Merrill Lynch highlights five biotechs that have been absolutely crushed but have outstanding potential and catalysts that can drive them much higher.
Ebola Stocks Move in Different Directions
Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brought a mixed view for this group.
Ebola Stocks on the Move
Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears.
Analyst Top Biotech Stocks Could Explode After Huge Sell-Off
In a new report, Stifel analysts highlight their top biotech stocks with strong earnings momentum and possible catalysts to buy right now.
Drug Sales Energize Johnson & Johnson Earnings
Johnson & Johnson reported better-than-expected third-quarter 2014 results before markets opened Tuesday.
Ebola Fears Driving Ebola Stock Winners
Fears of Ebola have plagued the United States since late September, and some biotech companies have capitalized on this fear.
UBS Very Positive on Top Biotech Stocks Ahead of Earnings
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Diplomat Turns Bunt Pricing Into Homerun for IPO Buyers
Diplomat Pharmacy priced its IPO shares at $13 on Thursday, but when the stock began trading Friday morning it opened at $16.